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HBV messing with the B-cell
genome leads to DLBCL
Marcella Visentini and Milvia Casato | Sapienza University of Rome Medical
School
In this issue of Blood, Ren et al report the results of a broad genomic and
transcriptomic analysis of hepatitis B virus (HBV)–associated diffuse large
B-cell lymphomas (DLBCLs) in Chinese patients, providing for the first time a
distinctive molecular profile of these tumors.1
Among the 275 DLBCL samples charac-
terizedbywhole-genome sequencing and
whole-exome sequencing, 20%were from
HBV infection surface antigen–positive
(HBsAg1) patients. This high proportion,
related to endemic HBV in China, provides
a unique opportunity for investigating dif-
ferences in clinical and mutational spec-
tra between HBV-related and -unrelated
DLBCL in the context of a common ethnic
background. HBsAg1 DLBCL patients
compared with HBsAg– patients had
significantly younger age, more aggres-
sive disease, and shorter survival, similar
to the findings in another study in Chinese
patients.2 Genome-wide analysis revealed
an increased total mutation load in HBsAg1
DLBCL possibly resulting from APOBEC
enzyme activity and also a distinctive set
of mutated genes that might be related to
the activity of the B-cell–specific activation-
induced cytidine deaminase (AID). BCL6
was the lymphoma-related gene most fre-
quently mutated (79%) in HBsAg1DLBCL,
together with other genes involved in the
FOXO signaling pathway (CXCR4, KLF2,
and SGK1). The authors speculate that
alterations of the FOXO pathway might
promote the development of HBsAg1
DLBCL by inducing antigen-independent
tonic B-cell receptor signaling, and they
suggest BCL6 as an important therapeutic
target.
HBV and hepatitis C virus (HCV) share
hepatotropism and the capacity to induce
B-cell lymphomas.3 In the case of HCV,
it is generally agreed that lymphomas
develop as a consequence of the pro-
tracted stimulation of B cells expressing
specific stereotyped idiotypes putatively
directed to a viral antigen that has not yet
been identified.4 A major argument in
favor of this hypothesis is the frequent
regression of indolent lymphomas asso-
ciated with HCV, but not with HCV1
DLBCL, after the clearance of infection
with antiviral therapy.5 Ren et al char-
acterized the V(D)J region of immuno-
globulin (Ig) heavy chain in 15 HBsAg1
DLBCL samples and were unable to iden-
tify recurrent stereotyped idiotypes. This
contrasts with another study2 in HBsAg1
DLBCL Chinese patients that identified 2
stereotyped sequences in 4 of 16 patients
studied and claimed significant homology
of these antibodies to antibodies specific
for HBsAg.
On the basis of their results, Ren et al
rejected the hypothesis that HBV, like
HCV, causes lymphomas by protracted
antigenic stimulation of B cells that pro-
duce virus-specific antibodies and sug-
gest that infection of B cells by HBV may
induce a hyperactive status that leads to
enhanced mutagenesis mediated in part
by APOBEC and AID. Indeed, these
2 hypotheses might not necessarily be
mutually exclusive. In the case of HCV, for
which an antigen-driven mechanism of
lymphomagenesis is generally accepted,
it has also been shown6 that infection of
B cells by the virus induces a mutator
phenotype that leads to a five- to 10-fold
increase in mutation frequency in BCL6,
Ig heavy chain, and p53 genes. Con-
versely, it is also known that some HBV-
infected individuals develop type 2 mixed
cryoglobulinemia, a monoclonal B-cell lym-
phoproliferative disorder that can regress
after infection is suppressed by antiviral
therapy.7 This suggests antigenic pressure
as the cause of monoclonal lympho-
proliferation because that is the case for
HCV-related mixed cryoglobulinemia.
HCV causes a large spectrum of lympho-
proliferative disorders ranging from the
most frequent mixed cryoglobulinemia,
which is benign but highly prone to
neoplastic evolution, to indolent lym-
phomas mainly originating frommarginal
zone B cells, to aggressive DLBCL. This
suggests that evolution from benign
monoclonal lymphoproliferation to aggres-
sive lymphoma may be driven by continual
antigenic stimulation and accumulation of
mutations. By contrast, HBV rarely causes
mixed cryoglobulinemia, andHBV-related
indolent lymphomas are much rarer than
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HBV-related DLBCL in Chinese patients.8
This large predominance of DLBCL over
indolent lymphoproliferative disorders
supports a model of HBV-driven muta-
genesis directly leading to DLBCL rather
than that of stimulation-driven progres-
sion from indolent to aggressive forms.
HBV-driven mutagenesis might occur by
a hit-and-run mechanism, because Ren
et al could not detect any HBV DNA in-
tegrated into DLBCL cells. Nevertheless,
the continual antigenic stimulation model
still stands as themost likely explanation for
HBV-dependent mixed cryoglobulinemia
(see figure).
The large body of data from Ren’s study
provides a framework for deciphering
the mechanisms by which HBV alters
the B-cell genome up to development of
DLBCL and, importantly, identifies potential
therapeutic targets for these aggressive tu-
mors. Future studies should clarify whether
the distinctive molecular signatures found
in HBsAg1 DLBCL Chinese patients are
also present in patients of Western origin.
In addition, the issue of whether virus-
specific stereotyped idiotypes may be in-
volved in some HBV-associated monoclonal
lymphoproliferative disorders2,7 should be
further addressed.
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Surviving childhood
cancer: a sobering story
Mary Eapen | Medical College of Wisconsin
Childhood cancers account for <1% of all cancers diagnosed, which amounts to
∼157 000 new cases annually. The table shows the common types of cancer and
percentage of occurrence; leukemia and brain tumor account for more than
half of all childhood cancers. In this issue of Blood, Holmqvist et al report on the
long-term survival of 362 survivors of childhood cancer whowere in continuous
remission and alive 2 years after autologous hematopoietic cell transplantation.1
Overall, there was a 23-fold increase in
late mortality compared with that in an
age- and sex-matched general popula-
tion. Recurrent primary disease was the
predominant cause of mortality in the first
10 years after transplantation and the cause
for half of all deaths in their cohort. The
2 other major causes of late mortality were
a second cancer and infection, each ac-
counting for ;20% of deaths.
In children, autologous transplantations
are reserved for high-risk solid tumors
(as consolidation therapy) and for Hodgkin
and non-Hodgkin lymphoma. Because the
study population in Holmqvist et al dates
back to 1980, about 25% of transplan-
tations were for acute lymphoblastic or
myeloid leukemia. Because autologous
transplantations are no longer offered for
acute leukemia in children, subset anal-
yses that excluded childhood survivors
of acute leukemia were undertaken; the
analyses confirmed that the risks for late
mortality were consistent with those ob-
served for the whole cohort. Although
mortality rates decline in those who sur-
vive for more than 10 years, the numbers
of patients are substantially fewer. Studies
that include an adequate number of very
long-term survivors are needed to under-
stand the risks of late mortality in these
survivors.
A recent report on late mortality from
Canada observed that 25% of long-term
survivors of autologous transplantation
suffered a later death (death occurring
.2 years after transplantation).2 Yet there















HBV might exploit 2 different mechanisms for causing
either indolent (mixed cryoglobulinemia) or highly
malignant (DLBCL) B-cell lymphoproliferative disor-
ders. In the case of DLBCL, HBV infection of B cells
may enhance overall mutagenesis (possibly through
APOBEC enzymes) and alter B-cell–specific signaling
pathways (possibly through AID). Among the latter,
alterations in the FOXO pathway might result in lym-
phomagenic tonic B-cell receptor signaling. DLBCL
cells do not seem to express stereotyped idiotypes
putatively recognizing HBV antigens. Conversely, in
mixed cryoglobulinemia, continual antigenic stim-
ulation by HBV may drive the clonal expansion of
B cells expressing specific stereotyped idiotypes
that regress upon suppression of infection by antiviral
therapy. There is no evidence suggesting the possi-
bility of progression from mixed cryoglobulinemia to
DLBCL.
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